Skip to Content
Merck
  • HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.

HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.

Frontiers in pharmacology (2018-01-13)
Wen-Tsung Huang, Yu-Hsuan Tsai, Shang-Hung Chen, Ching-Wen Kuo, Yao-Lung Kuo, Kuo-Ting Lee, Wen-Chung Chen, Pei Chih Wu, Chun-Yu Chuang, Siao Muk Cheng, Chun-Hui Lin, Euphemia Yee Leung, Yung-Chieh Chang, Chun Hei Antonio Cheung
ABSTRACT

Intrinsic or acquired resistance to hormone therapy is frequently reported in estrogen receptor positive (ER

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bovine Serum Albumin, lyophilized powder, ≥96% (agarose gel electrophoresis)
Sigma-Aldrich
MISSION® esiRNA, targeting human HDAC2
Sigma-Aldrich
CelLytic M, Cell Lysis Reagent, Suitable for Mammalian cell lysis and protein solubilization.
Sigma-Aldrich
Anti-ATG5 Antibody, clone 177.19, clone 177.19, from mouse
Sigma-Aldrich
Anti-Sp1 Antibody, Upstate®, from rabbit
Sigma-Aldrich
Anti-Actin Antibody, clone C4, ascites fluid, clone C4, Chemicon®